CID-103 not checked

CASI pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of 6 months.”In the company’s words, NCT07946549 on ClinicalTrials.gov
Tested for
Chronic Immune Thrombocytopenia (2 trials), Antibody Mediated Rejection
Main trialPhase 2
“The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP). The main questions the study aims to answer are: * To evaluate the safety and tolerability of CID-103 in subjects with ITP with different increasing doses of CID-103. * To further evaluate the safety and tolerability of CID-103 at two or three dose levels and to select an optimal dose and administration regimen for CID-103 for further study of clinical efficacy. The study will be done in two parts:…”In the company’s words, NCT07946549 on ClinicalTrials.gov

Other drugs for Chronic Immune Thrombocytopenia

All 36 drugs for Chronic Immune Thrombocytopenia

Coming up2

Changes1

Last 90 days

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting 30 Nov 2028 A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
Phase 1/2Recruiting 1 Jun 2026 A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
Phase 1/2Recruiting May 2030 A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).
Phase 1Completed 19 Jan 2023 CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CID-103

Following is part of Solo: you see every change to CID-103 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in